Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00504166 · ClinicalTrials.gov registry record · Phase 4
Alendronate Prevents Microarchitectural Deterioration of Trabecular Bone in Early Postmenopausal Women
A Phase 4 study of Osteoporosis and Osteopenia, sponsored by University of California, San Francisco.
- Completed
- Registry status
- Phase 4
- Development phase
- 53
- Enrollment target
- 1
- Study location
NCT00504166: Completed Phase 4 study of Osteoporosis and Osteopenia, sponsored by University of California, San Francisco.
NCT00504166 is a Phase 4 study of Osteoporosis and Osteopenia that has completed, run by University of California, San Francisco. The registered enrollment target is 53 participants, below the 1,545-participant average among 84 other Osteoporosis trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00504166, a Phase 4 study of Osteoporosis and Osteopenia, has completed, sponsored by University of California, San Francisco.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 53 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to evaluate the changes in bone structure as determined by magnetic resonance imaging measurements among early postmenopausal women after 24 months of treatment with alendronate, 70 mg once a week as compared to placebo
Primary Outcome
Trabecular number is a three-dimensional measure of the mean inter-trabecular distance; the primary micro-architectural feature measured by high-resolution CT imaging. The parameter was calculated from scans of the distal radius and distal tibia at baseline, 12, and 24 months. The percent change from baseline over these time periods was calculated as the primary outcome measure indicating the micro-architectural status of trabecular bone.
Conditions Studied
Interventions
- DRUG alendronate sodium
- OTHER placebo comparator
Study Locations (1)
California
- University of California Department of Radiology - San Francisco
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 53 participants |
| Start Date | 2006-02 |
| Est. Completion | 2009-04 |
| Phase | Phase 4 |
What the finished NCT00504166 record still lists
NCT00504166 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 53 participants, a relatively small participant target, below the 1,545-participant average among 84 other Osteoporosis trials with a reported enrollment target (97% lower).
The record links to 2 conditions, with Osteoporosis appearing as the primary indexed condition, and to 2 interventions - of which alendronate sodium is the first listed.
NCT00504166 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT00504166 about?
NCT00504166 is a clinical study titled "Alendronate Prevents Microarchitectural Deterioration of Trabecular Bone in Early Postmenopausal Women". The purpose of this study is to evaluate the changes in bone structure as determined by magnetic resonance imaging measurements among early postmenopausal women after 24 months of treatment with alendronate, 70 mg once a week as compared to placebo
What is the current status of trial NCT00504166?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 53 participants. The study started on 2006-02. Estimated completion is 2009-04.
What conditions does trial NCT00504166 study?
This clinical trial studies the following conditions: Osteoporosis, Osteopenia.
What interventions are being tested in trial NCT00504166?
The interventions under investigation include: alendronate sodium (DRUG), placebo comparator (OTHER).
Who is sponsoring clinical trial NCT00504166?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00504166 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Osteoporosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00504166's enrollment target sits among peer trials
53 54th of 84 higher than 30 of 84 other Osteoporosis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Osteoporosis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Preserving Geriatric Muscle With an Osteoporosis Medication
RECRUITING · Phase 4
-
Combined Anabolic Therapy
RECRUITING · Phase 4
-
Treatment With Romosozumab Versus Denosumab to Improve Bone Mineral Density and Architecture in Subacute SCI
ACTIVE NOT RECRUITING · Phase 4
-
Denosumab (DMAB) Discontinuation and Switching in Glucocorticoid-Induced Osteoporosis (GIOP): a Pilot Study
ACTIVE NOT RECRUITING · Phase 4
-
Comparative Antiresorptive Efficacy Discontinuation of Denosumab
ACTIVE NOT RECRUITING · Phase 4
-
Trial of Parkinson's And Zoledronic Acid
ACTIVE NOT RECRUITING · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04177004 · 53 participants · Phase 1
Human Lysozyme Goat Milk for the Prevention of Graft Versus Host Disease in Patients With Blood Cancer Undergoing a Donor Stem Cell Transplant
- NCT04199741 · 53 participants · Phase 1
PET/CT Imaging of Small Cell Lung Cancer Using 89Zr-DFO-SC16.56
- NCT04835129 · 53 participants · Phase 2
Isatuximab, Pomalidomide, Elotuzumab and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma
- NCT04913805 · 53 participants · Phase 2
Matching Perfusion and Metabolic Activity in HFpEF
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia